Q5160 NDC Crosswalk, Billing Units, ASP Payment & Medicare Reimbursement

📋 Q5160 summary

Q5160 is a HCPCS Level II Q-code used to bill jobevne, 10 mg, billed per 10 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with Q5160: Jobevne

Code Q5160 Billing unit 10 MG Payment limit $82.236/unit NDC-Crosswalk 2 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeQ5160

DescriptorInj, jobevne, 10 mg

Billing unit10 MG

Payment limit / unit$82.236

Est. ASP / unit$77.581 est.

Mapped NDCs2

Data periodQ3 2026

Last updated2026-09-20

💊 About Bevacizumab Injection DRUG GUIDE

Bevacizumab injection is used to treat multiple types of advanced or metastatic cancers, most often in combination with chemotherapy.

Avastin is approved for metastatic colorectal cancer (when combined with specific fluorouracil-based chemotherapy regimens), non-squamous non-small cell lung cancer (first-line, with carboplatin and paclitaxel), recurrent glioblastoma in adults, metastatic renal cell carcinoma (with interferon alfa), persistent or metastatic cervical cancer, and hepatocellular carcinoma (liver cancer, in combination with atezolizumab for patients who have not yet received systemic therapy).Avastin is also approved for epithelial ovarian, fallopian tube, or primary peritoneal cancer — including stage III/IV disease after surgery, platinum-resistant recurrent disease, and platinum-sensitive recurrent disease — each with specific chemotherapy partner regimens.

Note that Avastin is not indicated for adjuvant (preventive post-surgery) treatment of colon cancer.

Read the full Bevacizumab Injection drug guide →

Clinical overview from our editorial drug guide for Bevacizumab Injection. For billing reference, see the sections above.

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).

Medicare payment limit / unit

$82.236

Est. ASP / unit

$77.581 est.

Est. after 2% sequester

$80.591

HCPCS dosage

10 MG

The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of Q5160 = 10 mg. Enter a regimen to convert dose → billing units and project a full course.

Dose per administration (mg) Frequency — every days Number of doses NDC / package billed (optional)

Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under Q5160 WITH EST. MEDICARE PAY

2 NDCs map to Q5160. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($82.236/unit) × that package's bill units.

NDC (11-digit)	Drug	Labeler	Package	Strength	Bill units	Est. pay / pkg	NADAC / unit	Status	Source
83257-0009-11	JOBEVNE bevacizumab-nwgd 25 mg/mL INJECTION	Biocon	1 VIAL, SINGLE-DOSE in 1 CARTON (83257-009...	25 mg/mL	10	$822.36	—	● Active	CMS + PDAC
83257-0010-11	JOBEVNE bevacizumab-nwgd 25 mg/mL INJECTION	Biocon	1 VIAL, SINGLE-DOSE in 1 CARTON (83257-010...	25 mg/mL	40	$3,289.44	—	● Active	CMS + PDAC

NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

⚠️ Don't confuse Q5160 with… RELATED CODES

Adjacent HCPCS codes that share an ingredient or formulation with Q5160. Billing units and payment limits differ — confirm the exact code, strength and form before billing.

Code	Descriptor	Billing unit	Payment limit / unit	How it differs from Q5160
Q5107	Inj mvasi 10 mg	10 MG	$24.533	Related ingredient or formulation — confirm strength, form and billing unit before substituting.
J9035	Bevacizumab injection	10 MG	$74.823	Related ingredient or formulation — confirm strength, form and billing unit before substituting.
Q5129	Inj, vegzelma, 10 mg	10 MG	$23.647	Related ingredient or formulation — confirm strength, form and billing unit before substituting.
Q5126	Inj alymsys 10 mg	10 MG	$79.944	Related ingredient or formulation — confirm strength, form and billing unit before substituting.
Q5118	Inj., zirabev, 10 mg	10 MG	$25.889	Related ingredient or formulation — confirm strength, form and billing unit before substituting.

Related codes matched on shared ingredient (CMS Medicare Part B Spending feed). Billing units and payment limits from the CMS ASP Pricing File. Always verify the precise HCPCS code for the product and strength administered.

📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)

Total Part B spend

$87.9K

Claims

15

Beneficiaries

11

Spend / beneficiary

$7,990.69

Spend / claim

$5,859.84

Where Q5160 ranks among Part B drugs · 2026 (Q1) · neighbors ±5

Total spending — #575 of 824

#570 ADRIAMYCIN* J9000 $97.4K #571 LEVALBUTEROL HCL J7614 $95.8K #572 STELARA(J3357)* J3357 $94.6K #573 PALISADE DM MATRIX P... Q4350 $94.1K #574 CISPLATIN J9060 $89.5K #575 JOBEVNE Q5160 $87.9K #576 CYSVIEW A9589 $85.5K #577 ABILIFY ASIMTUFII J0402 $83.9K #578 CEFTAROLINE FOSAMIL* J0712 $80K #579 DEFEROXAMINE MESYLAT... J0895 $78.6K #580 DAPTOMYCIN(J0872) J0872 $78.1K

Total claims — #805 of 824

#800 XWRAP DUAL, PER SQ C... Q4358 16 #801 BCG (TICE STRAIN)(90... 90586 15 #802 YESCARTA Q2041 15 #803 SURGRAFT XT PER SQ C... Q4269 15 #804 ARTACENT VERICLEN, P... Q4339 15 #805 JOBEVNE Q5160 15 #806 HAVRIX* 90632 14 #807 CLINDAMYCIN-0.9% NAC... J0737 14 #808 COAGADEX J7175 14 #809 PROGRAF(J7525)* J7525 14 #810 CLOFARABINE* J9027 14

Full breakdown by period (1)

Period	Total spend	Beneficiaries	Claims	$/beneficiary	$/claim
2026 (Q1)	$87.9K	11	15	$7,990.69	$5,859.84

Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📊 What bills under Q5160

J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.

NDC products by ingredient

bevacizumab-nwgd 4

NDC products by labeler

Biocon Biologics Inc. 4

Related NDC directory pages

🧪 All Bevacizumab-Nwgd NDCsIngredient 🏭 All Biocon labeler NDCsLabeler 83257 📚 All Vascular Endothelial Growth Factor Inhibitor NDCsDrug class

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.

HCPCS code & descriptor

CMS HCPCS Level II code file

Not available in current dataset

Payment limit & billing unit

CMS Medicare Part B ASP Pricing File (quarterly)

Q3 2026 · as of 2026-09-20

NDC ↔ HCPCS crosswalk

CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)

2 NDCs mapped

NADAC acquisition cost

CMS National Average Drug Acquisition Cost (weekly)

Not available for mapped NDCs

Utilization & spend

CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners

Latest data year 2026

Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ Q5160 billing FAQ

What is HCPCS code Q5160?

Q5160 is a HCPCS Level II Q-code used to bill Inj, jobevne, 10 mg under Medicare Part B and most medical (not pharmacy) benefits.

What is the billing unit for Q5160?

One unit of Q5160 represents 10 MG. Report the number of units equal to the dose administered divided by 10 MG.

How many units of Q5160 should I bill?

Divide the dose administered by the code's unit size (10 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.

How much does Medicare pay for Q5160?

The Medicare Part B payment limit is $82.236 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $80.591 per unit. Payment limits are revised quarterly.

Which NDCs bill under Q5160?

2 NDCs currently map to Q5160 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.

Does a crosswalk mean Q5160 is covered?

No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.

Q5160 – Inj, jobevne, 10 mg · NDC Crosswalk & Billing Units